SurvodutideCheck methods and identity
How SYNCHRONIZE-2 measured weight in adults with type 2 diabetes
2 numbered sourcesSource years 2026
Peptides are short chains of amino acids held together by peptide bonds. Some mimic hormones or activate the receptors that respond to them. Survodutide is an investigational peptide that activates the glucagon receptor and the GLP-1 receptor. The phase 3 SYNCHRONIZE-2 trial asked what happened to body weight in adults with type 2 diabetes and excess body weight who were assigned to survodutide or placebo. [1]
The multinational, double-blind study compared two survodutide groups and one placebo group. The paper reports results for 752 participants who received a trial intervention. Eligibility required a body mass index of at least 27 and a diagnosis of type 2 diabetes. At the start, the average age was 56 and the average body mass index was 36.5. The researchers specified two main outcomes at 76 weeks: the average percentage change in weight and the share of people who lost at least 5% of their starting weight. A large average reduction can occur even if many participants do not reach a particular threshold. [1]
The estimated mean reductions were 8.2% and 9.8% in the two active groups, compared with 3.9% with placebo. About 58% and 65% of participants in the active groups reached a weight reduction of at least 5%, compared with about 35% with placebo. The analysis was designed to include the effect of events such as stopping or interrupting the assigned treatment and using another obesity treatment. Its estimates describe the comparison under those rules and the trial’s follow-up. [1]
Subtracting the placebo group's average reduction gives differences of 4.3 and 5.9 percentage points for the two survodutide groups. These group averages cannot predict how much an individual will lose. The 76-week results also do not establish how much weight participants might keep off after the trial ends. [1]
The researchers also measured HbA1c, which reflects blood sugar exposure over several months. Average reductions were 0.9 and 0.8 percentage points in the active groups and 0.2 in the placebo group. Gastrointestinal adverse events were more common with survodutide. The trial reported such events in roughly three quarters of participants in the active groups and less than two fifths of participants in the placebo group. Most were described as mild to moderate and temporary. The weight and glucose results show average changes, while the adverse-event information describes part of what happened during treatment. [1]
The study tested a specific investigational product in adults with type 2 diabetes. A separate phase 3 trial enrolled adults without diabetes. Comparing the two reports can show how the programs approached different populations. It cannot isolate diabetes status as the reason for differences between average outcomes across the trials. The SYNCHRONIZE-2 result comes from the randomized comparison within its own group, and the research does not constitute an approval for the intervention. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
